Home | AI powered stock trade ideas | Market Signals | Breaking Out | New Green Signal Stocks | Recent Red Arrow Top Signals | Recent Green Arrow Bottom Signals | Near Term Bottom Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

Recently Featured Stock Charts
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart

StockChartsAI.com

All Chart Prices as of Previous Day Close

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Last Price: 90.33 - Change: 0.01 - Change %: 0.0111
04/17/2024 16:00:00 EST

Natera Inc (NTRA)

Industry: Diagnostics & Research

Price Support Resistance

In the past 20 trading days, NTRA has been trading in a range between $97.48 and $90.00 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

The AI powered stock chart is in a Yellow zone which means the stock is transitioning zones. We would avoid this stock currently.

Upside / Downside Potential

Natera Inc $NTRA entered a Yellow zone 2 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $71.2, a potential down side of -21.18% from the recent price of 90.33. Our AI powered stock target predictor currently has a target price of $27.32 a potential move of -70%. The stock is trading 9.4% (potential upside) below its 52 week high of $98.82 and 144.8 % (potential downside) above its 52 week low of $36.90 - based on the recent price.

Company Summary

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

NTRA Website

News

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here. The ProActive study is the largest prospective dd-cfDNA study in kidney transplant recipients, with roughly 5,000 patients enrolled a.
Source: Business Wire
Thu, 11 Apr 2024 08:00:00 -0400
Sentiment: Neutral
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA (dd-cfDNA) test to detect rejection in adult and pediatric heart transplant recipients. These are the second and third peer-reviewed publications evaluating Natera's technology for use in heart transplantation. “We are encouraged by the resul.
Source: Business Wire
Mon, 08 Apr 2024 08:00:00 -0400
Sentiment: Neutral
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera's personalized and tumor-informed molecular residual disease (MRD) test. Sponsored by Genentech, a member of th.
Source: Business Wire
Fri, 05 Apr 2024 07:00:00 -0400
Sentiment: Neutral
Showcasing Seeking Alpha's March 2024 New Analysts
There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered.
Source: Seeking Alpha
Thu, 04 Apr 2024 11:30:16 -0400
Sentiment: Positive
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National Cancer Institute (NCI), part of National Institutes of Health, today announced the launch of Alliance A032103 (MODERN), a randomized, phase II/III, biomarker-integrated trial. Alliance A032103 (MODERN) will utilize Signatera™, Natera's personalized and tumor-inf.
Source: Business Wire
Mon, 01 Apr 2024 08:00:00 -0400
Sentiment: Neutral
Instituions Institution %: 96.063
Last QTR Institution change: -206808

Insiders
Insiders %: 4.101
Insiders Purchases last QTR: 0
Insiders Sales last QTR: 364168
Insiders Net last QTR: -364168

Analyst Ratings
Target Price: 71.2
Overall Rating: 4.4118
Strong Buys (5): 10
Buys (4): 5
Holds (3): 1
Sells (2): 1
Strong Sells (1): 0

Technicals
52 Week Hi: 98.82
52 Week Low: 36.9
Beta: 1.393
50 Day MA: 84.5286
200 Day MA: 60.6255

Earnings / Revenue Trends
Qtr Earnings Growth YOY: 0
Qtr Revenue Growth YOY: 0.432
Forward PE: 0
Trailing PE: 0

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!

1000

Stock Analyzed Each Night

Portfolio

Easily Upload Track Your Stocks

Trends

See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.